SMS Pharmaceuticals gets EIR for Kandivalasa facility

| Updated on March 11, 2020

SMS Pharmaceuticals on Thursday announced the successful closure of inspection with the receipt of Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). The inspection was conducted by the USFDA at its API facility Kandivalasa, Andhra Pradesh, during January 13-17. This facility predominantly caters to regulated markets including the US, it said. Shares of SMS Pharma slumped 8 per cent at ₹34.40 on the BSE.

Published on March 11, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like